Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationS Brown, M. Miles Braun, Evelyne T. Edwards et al.|Arthritis & Rheumatism|2002Cited by 661
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanerceptJong‐Hoon Lee, M. Miles Braun, Jeffrey Siegel et al.|Arthritis & Rheumatism|2002Cited by 448
<i>Listeria monocytogenes</i> infection as a complication of treatment with tumor necrosis factor α–neutralizing agentsNancy R. Slifman, M. Miles Braun, Sharon K. Gershon et al.|Arthritis & Rheumatism|2003Cited by 387
Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.Niveditha Mohan, M. Miles Braun, Evelyne T. Edwards et al.|PubMed|2004Cited by 198
Drug-induced systemic lupus erythematosus and TNF-α blockersAparna Mohan, M. Miles Braun, Timothy R. Coté et al.|The Lancet|2002Cited by 82